Remove 2028 Remove Compounding Remove Immunization
article thumbnail

There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma

Pharmaceutical Technology

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4

article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.

Dosage 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

Pharmacy Times

months versus 2.1 months versus 2.1 The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

This high compound annual growth rate of 23.6% was powered by the advent of immune-checkpoint inhibitors, added Chalk. These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. GlobalData is the parent company of Pharmaceutical Technology.

Immunity 105
article thumbnail

N-FIS was developed to address a critical challenge in healthcare—needle phobia

Express Pharma

Additionally, we are expanding our regulatory approvals to enter international markets and are engaging with global health organisations to integrate needle-free technology into immunization programs, making injections safer and more accessible worldwide. billion in 2028, growing at a compound annual growth rate (CAGR) of 14.16

article thumbnail

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

PharmaTech

billion and an additional $2 billion in non-contingent anniversary payments through 2028. s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry Christopher Cole June 10th 2025 Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond.

Dosage 52